My point is that the most relevant data Imugene considers useful...

My point is that the most relevant data Imugene considers useful is the 15% which Leslie has mentioned in email to a shareholder can’t remember to whom.

The other data isn’t safer as it’s not apples for apples, again that’s IMU’s viewpoint from emails we’ve received. Disagree as you like with that but I wouldn’t mock people for that view point. ie agreeing with the actual scientists.

One could easily form the view that as the dose escalates those rates of pseudoprogression might fall in line with similar therapy. Which CF33 has outperformed preclinically (TVec) not unreasonable to expect newer therapies to potentially go a step further as well..
We are still waiting to see.